Loading stock data…
ORIC
$9.77-0.11 (-1.11%)
Market ClosedLast close May 1
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ORIC Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.77. The stock is currently 35% below its 52-week high of $14.93, remaining 11.3% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why ORIC maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.77
Potential Upside
5%
Whystock Fair Value$10.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$21.00+114.9%
Range$15.00 – $25.00
Fundamentals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozerti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.69%
Volume
Today's trading volume
1.18M
Recent News
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
ORIC Pharmaceuticals (ORIC) updated investors on Phase 1b data for rinzimetostat plus darolutamide in metastatic castration resistant prostate cancer, and selected a 400 mg daily dose for a planned global Phase 3 trial. See our latest analysis for ORIC Pharmaceuticals. The latest rinzimetostat update comes after a sharp 1 day share price return of 18.93% to US$8.89, following a 27.07% 7 day share price decline. The 1 year total shareholder return of 93.68% points to strong but volatile...
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
In late March 2026, ORIC Pharmaceuticals reported Phase 1b data showing that rinzimetostat 400 mg once daily plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer achieved strong early radiographic progression-free survival with mostly mild side effects, and selected this dose for the planned global Phase 3 Himalayas-1 trial. A key insight is that rinzimetostat’s exposure–response analysis suggested similar efficacy at 400 mg and 600 mg but meaningfully lower...
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges
Oric stock crashed Wednesday after the company indicated its prostate cancer treatment is roughly as effective as a competitor.
Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations
Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate-cancer drug candidate showed signs of a “best in disease” profile, the company said.